Dyne Therapeutics’ stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought ...

Cathie Wood just sent a clear signal with her moves, with her looking to trim stretched winners while doubling down on what ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can turn ...

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic. Click here for ...

BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

On July 8, Jared Holz, Mizuho, joined ‘Closing Bell Overtime’ on CNBC to discuss if the biotech sector is ready for a breakout. Jared Holz admitted that the biotech sector has been exceptionally ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.